Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics will post -4.03 earnings per share for ...

ByInvesting.com • Jun 11, 2024 Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) -- Conference call and webcast to be held... WALTHAM, Mass.

Check Out Our Latest Research Report on VRDN Viridian Therapeutics Trading Up 1.1 % NASDAQ VRDN opened at $19.43 on Tuesday. The company’s 50-day moving average price is $19.42 and its 200-day ...

Morning Star 30 69 Jan 23, 2025 20:00 ...

Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...